Investigating the role of p53 and SIRT1 in type 2 diabetes
Investigating the Impact of p53 and SIRT1 in the Development of Type 2 DM Through the Treatment of Prediabetic Individuals by Either Nigetella Salivata or Metformin
This study is testing whether treating prediabetic people with either Nigella sativa or Metformin can help understand how certain proteins affect the development of type 2 diabetes.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tanta University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT03925714 on ClinicalTrials.gov |
What this trial studies
This study examines how p53 and SIRT1 influence the development of type 2 diabetes by treating prediabetic individuals with either Nigella sativa or Metformin. The research aims to understand the mechanisms involved in diabetes progression and the potential benefits of these treatments. Participants will be monitored for changes in their metabolic health and diabetes risk factors throughout the intervention.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with prediabetes.
Not a fit: Patients who have confirmed diabetes or those with hepatic or renal impairment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide new insights into diabetes prevention and management strategies for prediabetic patients.
How similar studies have performed: Other studies have explored the roles of p53 and SIRT1 in metabolic conditions, but this specific approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Prediabetic subjects. Exclusion Criteria: * Confirmed diabetes. * Hepatic or renal impairment.
Where this trial is running
Cairo
- Sherief Abd-Elsalam — Cairo, Egypt (Recruiting)
Study contacts
- Principal investigator: Eman SA Sawan, Msc — Tanta University - Faculty of Pharmacy
- Study coordinator: Sherief Abd-Elsalam, ass. prof.
- Email: sheriefabdelsalam@yahoo.com
- Phone: 00201147773440
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.